HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $70
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $69 to $70.
Last updated: 2026-11-19 11:56:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Greenwich LifeSciences, Inc. (GLSI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21.00, with a market capitalization of $274.48M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.78 to $34.10. This page covers its latest market performance, valuation, price trends and company information.
$274.48M | |
$20.68 | |
$21.00 | |
$20.68 | |
$20.58 | |
185.00 | |
155.26K | |
-- | |
$34.10 | |
$7.78 | |
-- | |
2026-06-30 |
Greenwich LifeSciences, Inc. (GLSI) is trading at $21.00 in pre-market trading as of 2026-11-19 11:27:00, up 2.04% ($0.42) from the previous close of $20.58
Pre-market trading shows how investors are pricing GLSI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
GLSI is up 2.04% in pre-market trading.
Over the past seven days, Greenwich LifeSciences, Inc. (GLSI) moved from $16.07 to $21.00, representing a gain of 30.68% ($4.93).
The stock traded between $13.38 and $21.98 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 352.51 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.2%
GLSI is currently trading at $21.00, placing it 50.2% of the way from its 52-week low of $7.78 to its 52-week high of $34.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Greenwich LifeSciences, Inc. and GLSI stock.
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $69 to $70.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q3 earnings
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 48.15 percent decrease over losses of $(0.27) per
Greenwich LifeSciences announced that two abstracts on its Phase III FLAMINGO-01 clinical trial evaluating GLSI-100 immunotherapy for breast cancer recurrence prevention have been accepted for presentation at the San Antonio Breast Cancer Symposium 2026. The company will present two posters on December 9, 2026, authored by the FLAMINGO-01 Steering Committee.
Eligible investors can buy real shares of Greenwich LifeSciences, Inc. (GLSI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GLSI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GLSI shares and USD.
GLSI Shares to USD
1.00 GLSI shares = 21 USD
Calculations are estimates based on the latest available price and are for reference only.